JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the 11 Dirt Cheap Stocks to Buy According to Analysts. On October 3, JPMorgan increased its price target on Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from $23 to $26 while keeping an Overweight rating.

This decision comes as part of the firm’s preview for Teva Pharmaceutical Industries Ltd.’s (NYSE:TEVA) Q3 earnings. JPMorgan expects to see no surprises.

Previously, on September 24, UBS had also increased its price target on Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from $23 to $26 while keeping a Buy rating.

UBS raised its sales forecast for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) for 2030 from $6.3 billion to $6.6 billion. This includes potential revenue from the company’s Dual-Action Asthma Rescue Inhaler (ICS/SABA), expected to start in 2028. UBS expects this product to reach adjusted peak sales of $700 million in 2032.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company that focuses on innovative biopharmaceuticals and its leading generics business.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best American Semiconductor Stocks to Invest In and 12 Best Fintech Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.